Cancer

Niraparib extends time without symptoms in ovarian cancer

(HealthDay)—Women with recurrent ovarian cancer who receive the poly ADP ribose polymerase (PARP) inhibitor niraparib as maintenance therapy after treatment have both more time without side effects and significantly longer ...

Cancer

Researchers discover a common link among diverse cancer types

Cancer, in all its forms, seems to always involve uncontrolled cell growth; but there are thousands of ways in which cells can lose control of their proliferation in the first place. Among a huge variety of proteins known ...

Cancer

Burden of myeloproliferative neoplasms in Australia revealed

New research led by Cancer Council Queensland and Curtin University has investigated the patterns and trends of a rare group of blood cancers known as myeloproliferative neoplasms (MPN) for the first time in Australia.

page 1 from 3